NCT04144608 (TOGATHER) is a Phase 2 clinical trial of Toripalimab in Advanced Non Small Cell Lung Cancer, sponsored by Yongchang Zhang.

Who is sponsoring NCT04144608?

NCT04144608 is sponsored by Yongchang Zhang.

What drugs are being tested in NCT04144608?

Interventions in NCT04144608: Toripalimab.

What condition does NCT04144608 study?

NCT04144608 studies Advanced Non Small Cell Lung Cancer.

Is NCT04144608 still recruiting?

NCT04144608 is currently completed. Last updated 9 August 2024.

Last reviewed 2024-08-09 · How we verify

NCT04144608: TOGATHER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC

Completed Phase 2 Last updated 9 August 2024

What this trial tests

Phase 2 trial testing Toripalimab in Advanced Non Small Cell Lung Cancer in 40 participants. Completed in 30 July 2023.

Timeline

16 January 2020

Primary endpoint
30 June 2022

30 July 2023

Quick facts

Lead sponsor	Yongchang Zhang
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	16 January 2020
Primary completion	30 June 2022
Estimated completion	30 July 2023
Sites	1 location across China

Drugs / interventions tested

Toripalimab (TORIPALIMAB) — full drug profile →

Conditions studied

Advanced Non Small Cell Lung Cancer — all drugs for Advanced Non Small Cell Lung Cancer →

Sponsor

Yongchang Zhang — full company profile →

Who can join

Adults 18 to 70, any sex, with Advanced Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study was to investigate the efficacy of Toripalimab Combined with Double Platinum Based Chemotherapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments.
Czarnomysy R, Radomska D, Szewczyk OK, Roszczenko P, et al · · 2021 · cited 47× · PMID 34361037 · DOI 10.3390/ijms22158271
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.
Yusoh NA, Ahmad H, Vallis KA, Gill MR. · · 2025 · cited 11× · PMID 40518502 · DOI 10.1007/s12032-025-02812-3
Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.
Wu X, Chau YF, Bai H, Zhuang X, et al · · 2022 · cited 10× · PMID 36761426 · DOI 10.3389/fonc.2022.1099304
Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
Zheng Y, Feng B, Chen J, You L. · · 2023 · cited 9× · PMID 38106421 · DOI 10.3389/fimmu.2023.1273220
Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.
Yang N, Yue HL, Zhang BH, Chen J, et al · · 2023 · cited 7× · PMID 37596822 · DOI 10.1111/1759-7714.15052
[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
Chen S, Zhao Z, Long H. · · 2021 · cited 5× · PMID 33910277 · DOI 10.3779/j.issn.1009-3419.2021.102.10
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.
Zeng L, Yan H, Jiang W, Qin H, et al · · 2025 · cited 2× · PMID 39892382 · DOI 10.1016/j.medj.2025.100574
The efficacy analysis of neoadjuvant chemoimmunotherapy followed by surgery in stage III locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
Yang X, He Y, Guo T, Fang J, et al · · 2025 · PMID 41029573 · DOI 10.1186/s12885-025-14744-2

Verify or expand the search:

Other trials of Toripalimab

Trials testing the same drug.

NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07423078 — Window of Opportunity in Preserving Laryngeal Function Trial · Phase 2 · recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting

Other recruiting trials for Advanced Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
NCT05777603 — Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer · Phase 1 · recruiting
NCT06107374 — Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG · Phase 2 · recruiting
NCT06406166 — Lifei Xiaoji Wan in Treatment of Advanced NSCLC · NA · recruiting
NCT04886401 — Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC · recruiting

Other Yongchang Zhang trials

Trials by the same sponsor.

NCT03807102 — Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer · Phase 1, PHASE2 · unknown
NCT04777175 — A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer · recruiting
NCT05530785 — Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT · NA · unknown
NCT06521034 — First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer · Phase 1, PHASE2 · completed
NCT04144569 — PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04144608 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yongchang Zhang
Last refreshed: 9 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04144608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing